News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
840,505 Results
Type
Article (86172)
Company Profile (649)
Press Release (753684)
Multimedia
Podcasts (131)
Webinars (14)
Section
Business (232288)
Career Advice (4126)
Deals (39714)
Drug Delivery (126)
Drug Development (90810)
Employer Resources (198)
FDA (18018)
Job Trends (17335)
News (395670)
Policy (39681)
Tag
Academia (2992)
Academic (1)
Accelerated approval (6)
Adcomms (25)
Allergies (83)
Alliances (56678)
ALS (86)
Alzheimer's disease (1477)
Antibody-drug conjugate (ADC) (151)
Approvals (17999)
Artificial intelligence (235)
Autoimmune disease (28)
Automation (12)
Bankruptcy (402)
Best Places to Work (12518)
BIOSECURE Act (22)
Biosimilars (120)
Biotechnology (447)
Bladder cancer (77)
Brain cancer (26)
Breast cancer (241)
Cancer (2105)
Cardiovascular disease (149)
Career advice (3533)
Career pathing (34)
CAR-T (165)
Cell therapy (462)
Cervical cancer (18)
Clinical research (72953)
Collaboration (811)
Company closure (2)
Compensation (477)
Complete response letters (28)
COVID-19 (2835)
CRISPR (46)
C-suite (233)
Cystic fibrosis (100)
Data (1985)
Decentralized trials (2)
Denatured (46)
Depression (41)
Diabetes (194)
Diagnostics (6773)
Digital health (9)
Diversity (9)
Diversity, equity & inclusion (48)
Drug discovery (118)
Drug pricing (98)
Drug shortages (17)
Duchenne muscular dystrophy (94)
Earnings (95945)
Editorial (40)
Employer branding (25)
Employer resources (167)
Events (128848)
Executive appointments (632)
FDA (19094)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (666)
Gene editing (106)
Generative AI (22)
Gene therapy (327)
GLP-1 (742)
Government (5120)
Grass and pollen (5)
Guidances (126)
Healthcare (20747)
Huntington's disease (26)
IgA nephropathy (29)
Immunology and inflammation (136)
Indications (26)
Infectious disease (2956)
Inflammatory bowel disease (157)
Inflation Reduction Act (11)
Influenza (46)
Intellectual property (89)
Interviews (813)
IPO (17706)
IRA (38)
Job creations (5189)
Job search strategy (2861)
Kidney cancer (11)
Labor market (46)
Layoffs (555)
Leadership (22)
Legal (10057)
Liver cancer (74)
Lung cancer (299)
Lymphoma (143)
Machine learning (7)
Management (65)
Manufacturing (311)
MASH (76)
Medical device (14315)
Medtech (14320)
Mergers & acquisitions (22292)
Metabolic disorders (615)
Multiple sclerosis (80)
NASH (22)
Neurodegenerative disease (104)
Neuropsychiatric disorders (23)
Neuroscience (1995)
NextGen: Class of 2025 (7666)
Non-profit (5059)
Now hiring (41)
Obesity (327)
Opinion (271)
Ovarian cancer (72)
Pain (74)
Pancreatic cancer (69)
Parkinson's disease (135)
Partnered (19)
Patents (209)
Patient recruitment (100)
Peanut (48)
People (64954)
Pharmaceutical (131)
Pharmacy benefit managers (14)
Phase I (22545)
Phase II (31724)
Phase III (23838)
Pipeline (1222)
Policy (150)
Postmarket research (3542)
Preclinical (10170)
Press Release (72)
Prostate cancer (91)
Psychedelics (34)
Radiopharmaceuticals (251)
Rare diseases (369)
Real estate (7384)
Recruiting (75)
Regulatory (26505)
Reports (56)
Research institute (2647)
Resumes & cover letters (649)
Rett syndrome (2)
RNA editing (5)
RSV (35)
Schizophrenia (72)
Series A (127)
Series B (75)
Service/supplier (25)
Sickle cell disease (49)
Special edition (20)
Spinal muscular atrophy (164)
Sponsored (34)
Startups (4287)
State (2)
Stomach cancer (11)
Supply chain (51)
Tariffs (44)
The Weekly (83)
Vaccines (755)
Venture capitalists (42)
Weight loss (230)
Women's health (37)
Worklife (20)
Date
Last 7 days (803)
Last 30 days (2493)
Last 365 days (28613)
2025 (9911)
2024 (34272)
2023 (42568)
2022 (53928)
2021 (58724)
2020 (57666)
2019 (51338)
2018 (39124)
2017 (37191)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1267)
Alabama (56)
Alaska (6)
Arizona (251)
Arkansas (8)
Asia (49904)
Australia (8803)
California (5651)
Canada (1644)
China (513)
Colorado (182)
Connecticut (227)
Delaware (141)
Europe (114302)
Florida (716)
Georgia (158)
Hawaii (1)
Idaho (64)
Illinois (464)
India (25)
Indiana (280)
Iowa (10)
Japan (145)
Kansas (113)
Kentucky (16)
Louisiana (13)
Maine (58)
Maryland (872)
Massachusetts (4417)
Michigan (192)
Minnesota (325)
Mississippi (1)
Missouri (57)
Montana (24)
Nebraska (26)
Nevada (59)
New Hampshire (52)
New Jersey (1614)
New Mexico (27)
New York (1575)
North Carolina (1032)
North Dakota (8)
Northern California (2481)
Ohio (172)
Oklahoma (13)
Oregon (45)
Pennsylvania (1188)
Puerto Rico (13)
Rhode Island (24)
South America (1649)
South Carolina (5)
South Dakota (1)
Southern California (2129)
Tennessee (30)
Texas (742)
United States (21026)
Utah (125)
Virginia (110)
Washington D.C. (41)
Washington State (528)
West Virginia (1)
Wisconsin (43)
840,505 Results for "121 bio".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Merida Biosciences Launches with $121M to Create Therapeutics for Multiple Autoimmune and Allergic Diseases
April 8, 2025
·
4 min read
Funding
Merida Enters Autoimmune and Allergy Arena With $121M Series A
Merida is working on a selective therapy for Graves’ disease, leveraging targeted therapies that can deplete disease-causing autoantibodies.
April 8, 2025
·
2 min read
·
Tristan Manalac
Neuroscience
GSK Dives Deeper Into Neuro With $2.5B+ ABL Bio Pact
GSK is paying to access ABL Bio’s Grabody-B platform, which potentially enables therapies to cross the blood-brain barrier.
April 7, 2025
·
2 min read
·
Tristan Manalac
C-suite
Biotech a Bright Spot for Female Founders Amid DEI Pullback
A new Pitchbook report found $4.3 billion in funding to women-fronted biotech companies across 121 deals. The increase comes as sociopolitical headwinds slam into initiatives to support women and minorities.
March 6, 2025
·
2 min read
·
Annalee Armstrong
Immunology and inflammation
Hillstar Bio Nets $67M Series A to Advance Autoimmune and Arthritis Pipeline
Led by alums from Takeda and Boston Pharmaceuticals, Hillstar Bio is working on treatments that remove harmful immune cells to relieve disease.
March 25, 2025
·
2 min read
·
Dan Samorodnitsky
Press Releases
RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock
February 11, 2025
·
6 min read
Press Releases
RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock
February 6, 2025
·
6 min read
BioCapital
REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II
REGENXBIO Inc. (Nasdaq: RGNX) today announced it completed a successful Pre-Biologics License Application (BLA) meeting for RGX-121 for the treatment Mucopolysaccharidosis Type II (MPS II), where it finalized details of its BLA with the U.S. Food and Drug Administration (FDA).
June 18, 2024
·
9 min read
Drug Development
FDA Approved Phase II/III Clinical Study of KPG-121 in Combination with Abiraterone as a First Line Treatment for mCRPC
Kangpu Biopharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has recently approved a Phase II/III clinical trial of KPG-121 in combination with Abiraterone for a first-line treatment of metastatic castration resistant prostate cancer (mCRPC).
June 5, 2024
·
1 min read
Layoffs
Passage Bio Cutting 55% of Staff to Help Extend Cash Runway
Passage Bio’s workforce reduction could affect about 32 people, leaving the company with 26 employees as it continues evaluating a treatment for frontotemporal dementia with granulin mutations.
January 13, 2025
·
1 min read
·
Angela Gabriel
1 of 84,051
Next
